INBRX-101/rhAAT-Fc not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).”In the company’s words, NCT03815396 on ClinicalTrials.gov
- Tested for
- Alpha-1 Antitrypsin Deficiency, AATD
- Main trialPhase 1
- “This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.”In the company’s words, NCT03815396 on ClinicalTrials.gov
Other drugs for Alpha-1 Antitrypsin Deficiency
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- FazirsiranTakeda · Phase 3
- WVE-006Wave Life Sciences · Phase 1/2
- BEAM-302Beam Therapeutics Inc. · Phase 1/2
- SAR447537Sanofi · Phase 2
- PM647aPrime Medicine, Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 18 Aug 2022 | Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026